RxDoctor Payments DataLook up a doctor →

Brittany Zeigler

Acute Care · Lima, OHNPI 1558996470

Payments from drug & device makers

$6,833in general payments, 2019–2025

Across 313 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$836
  • Pfizer$539
  • Incyte Corporation$498
  • AstraZeneca$474
  • E.r. Squibb & Sons, L.L.C.$379
  • Seagen Inc.$368
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$6,12090%
  • Education$71310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,833 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$26,735
Medicare patients
140
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate11$326,741
TagrissoOsimertinib Mesylate13$202,849
BosulifBosutinib13$192,287
XtandiEnzalutamide12$172,188
NubeqaDarolutamide12$160,869
EliquisApixaban21$21,515
XareltoRivaroxaban22$11,818
Anastrozole146$2,512
Letrozole41$836
Gabapentin61$817
Hydroxyurea35$368
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$235
Levothyroxine Sodium12$107
Mirtazapine15$92
Zolpidem Tartrate12$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerBosulif, Eliquis$539$213,80234 claims
AstraZenecaTagrisso$474$202,84913 claims
Astellas Pharma US IncXtandi$83$172,18812 claims
BayerNubeqa$37$160,86912 claims
Johnson & JohnsonXarelto$836$11,81822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.

Other acute care in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →